Log in to save to my catalogue

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-...

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2384844268

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundFew options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. MethodsIn...

Alternative Titles

Full title

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2384844268

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2384844268

Other Identifiers

ISSN

1470-2045,1474-5488

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(20)30068-1

How to access this item